PubMed · 13520539
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M PERRAULT, B CLAVEL. 1958. [Chelation: its therapeutic application].. https://pubmed.ncbi.nlm.nih.gov/13520539/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Addition of a benzyl substituent to the macrocyclic ring of DOTA has a substantial impact on the conformational ring flipping motion of the macrocycle in the resulting LnDOTA complexes. The p-NO2-benzyl substituent in the Ln(p-NO2-Bn-DOTA)- complexes lies in an equatorial position and effectively "locks" the conformation of the ring into the deltadeltadeltadelta configuration. The presence of the p-NO2-benzyl group also increases the population of the square antiprismatic (SAP) coordination isomer for all Ln(p-NO2-Bn-DOTA)- complexes relative to that seen for the respective LnDOTA- complexes. Despite this increase in SAP isomer population, the rate of water exchange in these complexes remains comparatively fast. The kinetic and thermodynamic stabilities of the Ln(p-NO2-Bn-DOTA)- complexes are also slightly lower than the corresponding LnDOTA- complexes but appear to be sufficiently high for in vivo use.
A unique peptide sequence of HGGHHG screening from a combinatorial synthetic peptide library showed a good chelating ability to bind a transition metal on a chip better than hexa-His peptide. It was directly conjugated with a His-Tagged proteins onto a chip in a mild aqueous solution and can be used this chip as a high throughput technique for protein array in order to detect and purify the His-Tagged proteins.
BACKGROUND: Human chorionic gonadotropin (hCG) is among the most common analytes available for point-of-care immunotesting, with most assays currently based on simple manual assay devices. However, as the importance of good analytical performance of rapid assays is increasingly emphasized, more sophisticated immunoassay techniques are needed to meet the future challenges of rapid yet quantitative POC testing. METHODS: We developed a simple, dry-reagent, all-in-one immunoassay for the quantitative measurement of hCG in whole blood, plasma, or serum. The noncompetitive assay equally measures intact, nicked, and hyperglycosylated hCG as well as nonnicked and nicked hCG beta-subunit with a rapid and simple procedure consisting of a 5-min, one-step incubation and, subsequent to washing, the measurement of time-resolved fluorescence directly from a wet well surface. RESULTS: The assay had a detection limit (background + 3 SD) of 0.4 IU/L hCG. The within-run CV was <15% down to 2 IU/L, and the assay was linear to 6000 IU/L. The within- and between-run CVs in heparinized whole blood and plasma were </=10% throughout the measured range (4.0-4400 IU/L). The mean (95% confidence interval) difference between whole blood and plasma was -42 (-24 to -61)% without hematocrit correction and 6.5 (-14 to 27)% with hematocrit correction (n = 106). Regression analysis with the Diagnostic Products IMMULITE 2000 hCG method yielded the following: slope (SD), 1.02 (0.01); y-intercept (SD), -6 (10) IU/L; S(y|x) = 99 IU/L (n = 124; range, 1.6-4746 IU/L; r = 0.995). CONCLUSIONS: Combined with the fully automated instrumentation, the 5-min, dry-reagent assay allows quantitative and reproducible determination of hCG in whole blood while sustaining the speed and simplicity of conventional rapid assays.